TISIDB

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm.
Domain	PF02423 Ornithine cyclodeaminase/mu-crystallin family
Function	Specifically catalyzes the reduction of imine bonds in brain substrates that may include cystathionine ketimine (CysK) and lanthionine ketimine (LK). Binds thyroid hormone which is a strong reversible inhibitor. Presumably involved in the regulation of the free intracellular concentration of triiodothyronine and access to its nuclear receptors.

> Gene Ontology [ TOP ]
Biological Process	GO:0006520 cellular amino acid metabolic process GO:0006553 lysine metabolic process GO:0006554 lysine catabolic process GO:0006575 cellular modified amino acid metabolic process GO:0007605 sensory perception of sound GO:0009063 cellular amino acid catabolic process GO:0009066 aspartate family amino acid metabolic process GO:0009068 aspartate family amino acid catabolic process GO:0009914 hormone transport GO:0010817 regulation of hormone levels GO:0016054 organic acid catabolic process GO:0018958 phenol-containing compound metabolic process GO:0042403 thyroid hormone metabolic process GO:0042445 hormone metabolic process GO:0044282 small molecule catabolic process GO:0046395 carboxylic acid catabolic process GO:0050954 sensory perception of mechanical stimulus GO:0070327 thyroid hormone transport GO:0072337 modified amino acid transport GO:1901565 organonitrogen compound catabolic process GO:1901605 alpha-amino acid metabolic process GO:1901606 alpha-amino acid catabolic process GO:1901615 organic hydroxy compound metabolic process
Molecular Function	GO:0003714 transcription corepressor activity GO:0016645 oxidoreductase activity, acting on the CH-NH group of donors GO:0016646 oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor GO:0042562 hormone binding GO:0047127 thiomorpholine-carboxylate dehydrogenase activity GO:0048037 cofactor binding GO:0050661 NADP binding GO:0050662 coenzyme binding GO:0070324 thyroid hormone binding
Cellular Component	GO:0005777 peroxisome GO:0005782 peroxisomal matrix GO:0031907 microbody lumen GO:0042579 microbody GO:0044438 microbody part GO:0044439 peroxisomal part

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-6788656: Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism R-HSA-71064: Lysine catabolism R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CRYM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CRYM in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CRYM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.262	0.526
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.116	0.872
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.534	0.361
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1.07	0.0498
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.349	0.244
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.707	0.567
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.84	0.18
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.179	0.847
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-2.11	0.025
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.9	0.549
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-1.701	0.408
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.316	0.283

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CRYM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	18.8	-18.8	0.28
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	22.2	-22.2	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CRYM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CRYM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CRYM. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CRYM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CRYM expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CRYM and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CRYM
Name	crystallin, mu
Aliases	thiomorpholine-carboxylate dehydrogenase; THBP; NADP-regulated thyroid-hormone binding protein; mu-crystalli ......
Chromosomal Location	16p12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CRYM collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CRYM.

ID	Name	Drug Type	Targets	#Targets
DB05235	NRP409	Small Molecule	CRYM, THRA	2

Browse CRYM